Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab

Authors:

Abstract
In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases.

This publication has 16 references indexed in Scilit: